Aditx Therapeutics Appoints Jeff Ramson, Wall Street Veteran and Founder of PCG Advisory as Senior Advisor, Capital Markets &...
August 03 2020 - 8:00AM
via NEWMEDIAWIRE – Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Jeff Ramson as Senior Advisor,
Capital Markets and Communications.
Mr. Ramson will advise, coordinate, and assist in the
implementation of Aditxt’s overall communications strategy with the
capital markets and shareholders. He is a well-regarded business
entrepreneur and innovator, with a proven track record of more than
25 years’ experience on Wall Street, raising capital and providing
strategic guidance for emerging public and private companies in
various stages of development. As Chief Executive Officer of PCG
Advisory, Inc., a leading investor relations and digital strategies
firm which he founded in 2008, Jeff has been a pioneer in the
intelligent use of social media to advance investor relations goals
and increase awareness among key stakeholders.
Amro Albanna, Co-founder and Chief Executive Officer of Aditxt,
stated, “I have worked closely with Jeff over the last few years
during the evolution of Aditxt from a private company through the
recent completion of our NASDAQ IPO. Jeff’s collective experience
in capital markets, investor relations, and digital communications,
ideally positions him to implement our vision of engaging the
capital markets and stakeholders into our mission.
Jeff Ramson added, “I have had the good fortune to work side by
side with Amro over the last two and a half years. His
dedication and commitment to execute on behalf of Aditxt are
unparalleled. We share the vision that building a large and diverse
community of engaged stakeholders is a foundation for building a
large community of quality, long-term investors. Aditxt has put
together a world-class team and I very much look forward to
contributing to the Company’s path to success.”
About Aditx Therapeutics
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. The immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system.
The immune reprogramming technology is currently at the
pre-clinical stage and is designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit, www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product development; the
Company’s intellectual property position; the Company’s ability to
develop commercial functions; expectations regarding product launch
and revenue; the Company’s results of operations, cash needs,
spending, financial condition, liquidity, prospects, growth and
strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
entitled “Risk Factors” in the Company’s prospectus, dated June 29,
2020, that was filed with the U.S. Securities and Exchange
Commission under File No. 333-235933, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s subsequent filings with the U.S. Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations:PCG Advisory:Jeff RamsonChief
Executive OfficerIR@aditxt.com 646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024